Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.

ABSTRACT:

Background and objectives

Inhibition of de novo pyrimidine synthesis in proliferating T and B lymphocytes by teriflunomide, a pharmacological inhibitor of dihydroorotate dehydrogenase (DHODH), has been shown to be an effective therapy to treat patients with MS in placebo-controlled phase 3 trials. Nevertheless, the underlying mechanism contributing to the efficacy of DHODH inhibition has been only partially elucidated. Here, we aimed to determine the impact of teriflunomide on the immune compartment in a longitudinal high-dimensional follow-up of patients with relapse-remitting MS (RRMS) treated with teriflunomide.

Methods

High-dimensional spectral flow cytometry was used to analyze the phenotype and the function of innate and adaptive immune system of patients with R

SUBMITTER: Tilly G 

PROVIDER: S-EPMC8552527 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature